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Chronic pain is one of the most common and debilitating health conditions. Treatments for chronic low
back pain typically focus on biomedical treatment approaches. While psychosocial treatments exist,
multiple barriers prevent broad access. There is a significant unmet need for integrative, easily accessible,
non-opioid solutions for chronic pain. Virtual reality (VR) is an immersive technology allowing innovation
in the delivery of behavioral pain treatments. Behavioral skills-based VR is effective at facilitating pain
management and reducing pain-related concerns. Continued research on these emerging approaches is
needed.
Objective
In this randomized controlled trial, we seek to test the efficacy of a self-administered behavioral skills-
based VR program as a nonpharmacological home-based pain management treatment for people with
chronic low back pain (cLBP).
Methods
We will randomize 180 individuals with cLBP to 1 of 2 VR programs: (1) EaseVRx (8-week skills-based
VR program); or (2) Sham VR (control condition). All participants will receive a VR headset to minimize
any biases related to the technology’s novelty. The Sham VR group had 2D neutral content in a 3D theater-
like environment. Our primary outcome is average pain intensity and pain-related interference with
activity, stress, mood, and sleep. Our secondary outcomes include patient-reported physical function, sleep
disturbance, pain self-efficacy, pain catastrophizing, pain acceptance, health utilization, medication use,
and user satisfaction. We hypothesize superiority for the skills-based VR program in all of these measures
compared to the control condition. Team statisticians blinded to treatment assignment will assess outcomes
up to 6 months posttreatment using an approach suitable for the longitudinal nature of the data.
Results
The study was approved by the Western Institutional Review Board on July 2, 2020. The protocol
(NCT04415177) was registered on May 27, 2020. Recruitment for this study was completed in July 2020,
and data collection will remain active until March 2021. In total, 186 participants were recruited. Multiple
manuscripts will be generated from this study. The primary manuscript will be submitted for publication in
the winter of 2020.
Conclusions
Effectively delivering behavioral treatments in VR could overcome barriers to care and provide scalable
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Chronic pain is one of the most common reasons adults seek medical care [1]. Chronic pain affects
between 50 and 116 million Americans, more than cancer, diabetes, and cardiovascular disease combined
[1-4]. Other estimates suggest that 25 million American adults live with moderate to severe chronic pain
(ie, pain scoring 4-7 on a visual analog scale and lasting over 3 months) that limits their activities and
diminishes their quality of life [5,6]. Because of this great need, it is imperative to develop and test
effective treatments for chronic pain.
Pain treatment and management often emphasize biomedical approaches, such as pharmacology or
surgical procedures. Historically, opioids were commonly prescribed for pain treatment and management.
These agents can yield both inconsistent and suboptimal results [7] and carry numerous personal and
public health risks. The Centers for Disease Control and Prevention (CDC), the Centers for Medicare &
Medicaid Services (CMS), and the Department of Health and Human Services recommended
nonpharmacological modalities as first-line treatments for pain, including behavioral treatments [8,9].
Low-risk behavioral treatments may facilitate improved outcomes and analgesia while minimizing health
risks.
Indeed, evidence-based behavioral treatments are effective for treating chronic pain. Therapies such as
cognitive behavioral therapy for chronic pain, mindfulness-based stress reduction [10,11], and acceptance
and commitment therapy [12] have been shown to modify cognitions and behaviors that influence the
perception of pain. Although behavioral therapies show some promise, multiple barriers prevent chronic
pain patients from accessing these behavioral treatment alternatives [13]. Strict reliance on skilled
therapists that are in short supply, travel burdens, long durations of treatments, inadequate insurance
coverage, and high costs can all contribute to a lack of treatment accessibility and patient engagement [14-
16]. Furthermore, almost 85% of patients do not report meaningful analgesia from their pain medications
(ie, they do not experience a long-term ≥50% reduction in their pain levels) [17]. Therefore, there is an
urgent need for effective and comprehensive solutions for chronic pain and behavioral treatment delivery
methods that are accessible to the entire spectrum of individuals affected by this concern.
Digital therapeutics for chronic pain are cost-effective, available on-demand, can be delivered in the home,
and improve the risk–benefit profile well above the current standard of care. In particular, virtual reality
(VR) therapeutics show promise as effective treatments for acute and chronic pain [18-24]. With the first
pain reduction VR program, SnowWorld, patients with pediatric burn undergoing physical therapy noted a
27%-44% reduction in pain (P<.05) in comparison to within-subject control [25]. To date, VR has been
used in numerous clinical settings to reduce pain and improve outcomes in complex regional pain
syndrome [26], chronic headache/migraine pain [27], fibromyalgia [28,29], and chronic musculoskeletal
pain [30]. Technology allows for an immersive, multisensory, and interactive virtual treatment experience.
By stimulating the visual, auditory, and proprioception senses, VR facilitates distraction to limit the user’s
processing of nociceptive stimuli, which has been shown in functional magnetic resonance imaging studies
[31]. Most importantly, VR therapeutics have the potential to enhance pain education and effectively
deliver evidence-based behavioral interventions.
A randomized clinical trial recently examined the effectiveness of a 21-day skills-based VR program for
chronic pain compared to the same content delivered in audio form [32]. The VR skills-based program was
superior in improving pain intensity and pain-related interference with activity, sleep, mood, and stress
compared to the audio-based treatment, with results strengthening after 2 weeks. Results suggested that
VR’s immersive components enhanced VR participants’ outcomes relative to those who completed an
audio treatment [31]. Nevertheless, it is unclear to what extent these positive outcomes were due to the VR
technology’s novelty and whether VR effects are durable. Therefore, this study seeks to conduct a
randomized controlled trial to test the effectiveness of a comprehensive 56-day behavioral skills–based VR
therapeutic program (skill-based VR) in chronic low back pain (cLBP). This study will elucidate the
immediate and long-term effects of this proposed treatment while comparing it to a nontherapeutic control
condition designed to account for this technology’s novelty.
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We hypothesize that therapeutic VR will significantly benefit self-reported pain intensity and pain-related
outcomes compared to our control condition throughout this 8-week treatment and follow-up period. This
study will address the following 4 objectives:
The primary objective is to assess the impact of skills-based VR on changes in patient-reported pain
and pain interference throughout an 8-week intervention and in comparison to a placebo VR
condition.
The secondary objective is to assess the impact of skills-based VR on changes in patient-reported
satisfaction (Patient’s Global Impression of Change [PGIC]) throughout an 8-week intervention and
in comparison to a placebo VR condition.
The tertiary objective is to assess the impact of skills-based VR on changes in patient-reported
opioid use, physical function, pain coping, and health outcomes immediately following the
intervention relative to a preintervention baseline and in comparison to a placebo VR condition.
The exploratory objective is to assess the impact of skills-based VR on changes in patient-reported
pain levels, opioid use, physical function, pain coping, health outcomes, and satisfaction for 6
months following intervention and in comparison to a placebo VR condition.
Methods
Overview
We will conduct a single-cohort, double-blinded (participant and analysts), cross-sectional, placebo-
controlled randomized clinical trial in which 180 community-based individuals with cLBP will be
randomly assigned to a 56-day skills-based VR therapeutic program (EaseVRx) and a 56-day control VR
condition (Sham VR). Participants will be followed for 8.5 months after randomization. Participant
eligibility will be assessed with an electronic screener survey. Once enrolled in the study, participants will
complete a 2-week baseline assessment period, an 8-week VR program, a posttreatment assessment, and
up to 4 posttreatment follow-ups over 6 months. During their 2-week baseline period, participants will be
required to complete their baseline assessment and at least one of three pain surveys in order to progress to
the treatment phase of the study in which they will receive a VR headset with their assigned treatment to
be completed at home (Figure 1).
Team statisticians blinded to participant treatment assignment will examine outcomes immediately
following treatment and after 1, 2, 3, and 6 months following treatment. The 6-month postintervention
assessment is exploratory. Our primary outcome will be average pain intensity and pain interference on
activity, sleep, mood, and stress. Our secondary outcomes include self-reported change in average pain
intensity, physical function, sleep disturbance, pain catastrophizing, pain self-efficacy, pain acceptance,
skills use, health utilization, medication use, and treatment usage and satisfaction.
The protocol for this trial has been approved by the Western Institutional Review Board. All participants
will be required to give their informed consent during their online screening before enrollment in the study.
Study Sample, Setting, and Recruitment
Community-based individuals with cLBP will be recruited nationally through chronic pain organizations
(eg, American Chronic Pain Association) and advertising on social media platforms such as Facebook and
Twitter. Additionally, study advertisements will be emailed to professional contacts at several medical
clinics with requests to forward among medical colleagues nationally. All advertisements will direct
interested individuals to a landing page where detailed study information exists. Interested individuals will
be directed to complete an online REDCap Cloud (nPhase, Inc.) screening form to assess their eligibility.
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The online screening will automatically classify individuals as eligible or ineligible using survey logic
based on our inclusion/exclusion criteria. Ineligible individuals will receive a message thanking them for
their interest and participation in the screening process, inform them of their ineligibility, and be given a
list of chronic pain resources. Eligible individuals will be redirected to an electronic consent form to
provide their signature and complete enrollment.
Enrolled participants will progress to the study’s treatment phase if they complete a baseline survey and at
least one of three pain surveys during the 2-week baseline period. Following the 2-week baseline period,
participants will be randomized to a treatment group. The study will enroll 180 adults (age 18-85 years)
with cLBP who meet study criteria (Textbox 1). This sample size accounts for expected attrition.
Inclusion and exclusion criteria. DVPRS: Defense and Veterans Pain Rating Scale; VR:
virtual reality.
Inclusion criteria
1. Men and women aged 18-85.
2. Diagnosis of low back pain without radicular symptoms.
3. Pain duration of at least six months.
4. Average pain intensity of ≥4 on the 0-10 DVPRS Pain Scale for the past month at screening.
5. English fluency.
6. Willing to comply with study procedures/restrictions.
7. Access to Wi-Fi.
Exclusion criteria
1. Unable to understand the goals of the study due to cognitive difficulty.
2. Current or prior diagnosis of epilepsy, seizure disorder, dementia, migraines, or other
neurological diseases that may prevent the use of VR.
3. Medical condition predisposing to nausea or dizziness.
4. Hypersensitivity to flashing light or motion.
5. No stereoscopic vision or severe hearing impairment.
6. Injury to eyes, face, or neck that prevents comfortable use of VR.
7. Cancer-related pain.
8. Moderate level of depressive symptoms (subclinical) as indicated by the Patient Health
Questionnaire-2 (PHQ) [33,34] depression screen score of >2.
9. Previous use of EaseVRx for pain.
10. Current participation in any interventional research study or completed participation in the past 2
months.
11. Currently pregnant or planning to become pregnant during the study period.
12. Does not have access to Wi-Fi during participation in the study.
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Skills-Based VR (EaseVRx)
13. Currently works at or has an immediate family member who works for a digital health company
or pharmaceutical company that provides treatments for acute or chronic pain.
Inclusion and Exclusion Criteria
Textbox 1 lists the inclusion and exclusion criteria. The reason that radicular symptoms were excluded was
to create a degree of homogeneity within the population recruited. Chronic lower back pain with radicular
symptoms is often treated differently from those that do have those symptoms. Additionally, we require
that participants be willing and available to participate during the study (8.5 months). Participants were
asked to complete biweekly surveys during the 56-day treatment to which they are assigned and complete
the posttreatment follow-up assessments (1, 2, 3, and 6 months).
Randomization and Blinding
Enrolled participants will be randomized 1:1 and assigned to 1 of 2 treatment arms: a 56-day skills-based
VR program (EaseVRx) and a 56-day control VR condition (Sham VR). Random assignment will rely on
REDCap Cloud’s automatic program to ensure blinded randomization and equal numbers in both treatment
arms. This will be a double-blinded study wherein participants and statisticians will be blinded to
treatment. An independent research coordinator will label each group as Group A and Group B randomly
before sending any data sets to the statistician. Three staff members (LG, IM, and BB) will be unblinded to
the treatment groups and will not be involved in any data analyses.
Study Interventions
Participants in both the EaseVRx and Sham VR conditions will receive a Pico G2 4K headset with either
EaseVRx or Sham VR condition. These devices will be mailed to the participant’s self-reported address.
Study staff will monitor participant progress through twice-weekly surveys of device use and provide
guided technical support. The following sections describe the components of the study interventions.
VR Headset and Software
This study will use a Pico G2 4K all in one head–mounted display that delivers VR images and sounds. We
selected the Pico G2 4K because it is commercially available, widely used, inexpensive, has minimal
visual latency, and is much easier for participants to use than many other devices. The user’s exhale, a
major mechanic of the EaseVRx program, is measured by the microphone embedded in the Pico G2
hardware, offering biodata-enabled immersive therapeutics. This hardware allows for displaying 3D
images (EaseVRx) and 2D images (Sham VR).
Participants randomized and allocated to this treatment arm will receive a
multimodal, skills-based, self-management VR program, called EaseVRx (AppliedVR), that incorporates
evidence-based principles of cognitive behavioral therapy and mindfulness. Developed by AppliedVR in
partnership with a pain psychology expert, the program provides pain neuroscience education and trains
users on evidence-based pain and stress management strategies via immersive and enhanced biofeedback
experiences. EaseVRx combines biopsychosocial pain education, diaphragmatic breathing training,
relaxation exercises, and executive functioning games to provide a mind–body approach toward living
better with chronic pain. The standardized 56-day program delivers a multifaceted combination of skills
training through a prescribed sequence of daily virtual experiences. Each VR experience lasts between 2
and 16 minutes, with an average duration of 6 minutes of treatment time. The VR treatment modules were
designed to minimize triggers of emotional distress or cybersickness. These modules include:
Interoceptive modules: biofeedback-like environments that shift in nature to reflect a progressively
enhanced state of relaxation.
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Sham VR
Education modules: visually guided lessons explain why the VR exercises are relevant to their pain
and specific topics relevant to behavioral medicine for pain.
360 video modules: high-quality 360 videos with voiceovers, music, breathing effects, and sound
effects that are designed to maximize relaxation and participant engagement.
Game modules: games are designed to maximize immersive distraction to decrease their perception
of pain.
Dynamic breathing modules: interactive virtual worlds where the user experiences a gamified
biofeedback session and is introduced to awareness of their breath via visualization. These modules
become increasingly challenging to better train participants in the practice of diaphragmatic
breathing.
VR-CORE guidelines suggest using an active control in VR clinical trials and promoting
nonimmersive, 2D content within a VR headset as an optimal placebo [23]. Thus, participants in the Sham
VR group will receive the same Pico G2 4K headset as participants in the immersive VR groups, but
instead of 360-degree, 3D, interactive content specially selected for efficacy, they will only view 2D nature
footage with neutral music layered on top that is selected to be neither overly relaxing nor distracting. The
experience of Sham VR is similar to watching a large-screen TV. The content that is displayed in the VR
sham will be viewed in a void theater. The void theater will consist of a solid black environment with the
2D content displayed on a “screen” in front of the user. The screen will take up a significant portion of the
field of view of the participant, but appear to be distant enough to minimize any sense of immersion
caused by viewing 3D content. The void theater screen will be fixed in place such that the user is capable
of looking away from the screen if they so choose. The content for the VR sham will be 2D stock nature
videos, all displayed in the void theater. The videos have been chosen to be more distracting than relaxing,
and the majority of them contain animals engaging in play, grazing, grooming, or other inoffensive
behaviors. There will be 20 videos that will be rotated over the 56 sessions, with a duration between 2.5
and 5 minutes, which corresponds directly with durations in the EaseVRx program. Figure 2 provides a
visualization of the kinds of content each VR program would provide.
Technical Support
Participants will be provided with onboarding material as well as emails describing the study procedures
and details. Instructional videos will be made available to participants, and access to remote technical
support will be provided. VR usage data for both treatment groups will be surveyed twice a week for the
intervention’s 8-week duration.
Survey data will be monitored for completion and technical support staff will be available. Participants
will receive a telephone number and email address to contact support staff as needed. The technical
support staff will also reach out if there is low adherence to the devices, lack of survey data, or low battery
power detected on the headset’s remote monitoring dashboard. Twice weekly, the research staff will review
the REDCap Cloud survey dashboard to assess if participants are completing the study. If a survey is
missed, the REDCap Cloud system will send up to 2 reminders 24 hours apart. If the participant does not
respond to the reminders, a research staff member will send an email or SMS text message to understand
why there has been no response and encourage them to re-engage with the study. If the survey remains
incomplete after 2 weeks of no data, the participant will be deemed lost to follow up. The participant could
come back to the study at any time.
Study Measures




Pain Interference With Activity, Mood, Sleep, and Stress
Patient Global Impression of Change
Physical Function and Sleep Disturbance (PROMIS)
Pain Catastrophizing
Pain Self-Efficacy
This section details the measurement and methods used to assess each variable. Table 1 outlines the
categories, name, rank, and number of items for all measures. The time interval for collecting these
measures is provided in Table 2.
Demographic variables will include age, gender, level of education, race, ethnicity,
employment status, annual household income, relationship status, duration of back pain (years since
onset), state of residence, and zip code. In order to perform geospatial coding, rural–urban commuting area
codes will be downloaded from a public data set provided by the United States Department of Agriculture
Economic Research Service. Using MS Excel, participant zip codes will be matched to the rural–urban
commuting area data set to classify participants living in rural or urban areas.
The Defense and Veterans Pain Rating Scale (DVPRS) [35] will be used to
measure average pain intensity over the previous 24 hours using an 11-point numeric rating scale (0=no
pain; 10=as bad as it could be; nothing else matters).
The DVPRS interference scale (DVPRS-II)
will be used to measure pain interference with activity, sleep, mood, and stress over the past 24 hours [36]
(0=does not interfere; 10=completely interferes).
Aligning with IMMPACT (Initiative on Methods, Measurement,
and Pain Assessment in Clinical Trials) recommendations for pain research [37,38], Patient Global
Impression of Change will be assessed using the question, “Since the beginning of VR treatment, how
would you describe the changes (if any) in activity limitations, symptoms, emotions and overall quality of
life-related to your low back pain?” on a 7-point scale ranging from 1 (No change or condition is worse) to
7 (A great deal better, and a considerable improvement that has made all the difference).
The NIH Physical Function and Sleep Disturbance
(PROMIS) [39] short-form measures will be used to assess physical function (version 6b [40]) and sleep
disturbance (version 6a [41]) over the past 7 days. Higher scores on physical function signify greater
function, whereas higher scores for sleep disturbance reflect greater symptom severity. The conversion
table within the scoring manuals, made available from the Person-Centered Assessment Resource [39,42],
will be used to calculate the individual short-form T scores using the Item Response Theory scoring
algorithms. Specifically, based on published item parameters, T scores (latent trait estimates) will be
computed for each individual’s response pattern using the Bayesian expected a posteriori method [43-45].
This has been widely applied within pain research [35-37,39-41,43-48].
The 13-item Pain Catastrophizing Scale (PCS) [49] is a validated instrument widely
used clinically and in pain research to assess patterns of negative cognition and emotion in the context of
actual or anticipated pain. Despite having discrete subscales for rumination, magnification, and feelings of
helplessness related to pain, prior work has shown that the PCS operates unidimensionally [50] and Cook
et al (unpublished). Aligning with prior work [32] and the goal of brevity, the following 4 PCS items will
be used: “It’s terrible and I think it’s never going to get any better,” “I become afraid that the pain will get
worse,” “I can’t seem to keep it out of my mind,” and “I keep thinking about how badly I want the pain to
stop.” Respondents rate the frequency with which they experience such thoughts on a scale from 0 (Not at
all) to 4 (All the time). The 4 numerical ratings will be summed to create a total score and index for pain
catastrophizing.
Pain Self-Efficacy was assessed in 2 ways. First, the 2-item Pain Self-Efficacy
Questionnaire (PSEQ-2) will be administered as a validated instrument used to assess respondents’
confidence in their ability to engage in various daily activities despite their chronic pain [51]. The PSEQ-2
consists of the following 2 items: “I can still accomplish most of my goals in life, despite the pain”, and “I
can live a normal lifestyle, despite the pain.” Respondents will use a 7-point scale to rate their response
from 0 (Not at all confident) to 4 (Completely confident). Scores for the 2 items are summed to create a







Prescription Opioid and Analgesic Medication Use
Health Care Utilization
Additional Custom Surveys
total score. Second, participants will be asked to rate their overall confidence in their ability to manage
their pain on a 10-point scale with 1 (Not at all Confident) to 10 (Very Confident). Following the
intervention, this section will be divided into 2 items measuring their overall confidence levels while
inside of VR and outside of VR.
The Chronic Pain Acceptance Questionnaire (CPAQ-8) short form is an 8-item
validated instrument that assesses one’s engagement in personally meaningful activities despite pain, as
well as efforts directed at controlling pain (example item: “I am getting on with the business of living no
matter what my level of pain is”) [52]. Respondents rate each item using a 6-point scale ranging from 0
(never true) to 5 (always true).
The custom device utilization survey is a single-item instrument that assesses the
number of VR sessions completed since the last time it was asked. Respondents select either (1) 0, (2) 1,
(3) 2, (4) 3, or (5) 4 or more. This survey is administered on a biweekly basis.
The System Usability Scale is a validated, 10-item attitude Likert scale giving a
global view of subjective assessments of usability (example item: “I thought the system was easy to use.”)
[53]. Participants rate each item using a 5-point response scale ranging from "Strongly Disagree" to
"Strongly Agree." Some items are reverse scored, a multiplier is applied to the sum total, and total SUS
scores range from 0-100.
The Immersive Tendencies Questionnaire (ITQ) is a 29-item
survey that measures difference in tendencies of individuals to experience presence [54]. The involvement
subscale was chosen by the coauthors to reduce participant burden with just 7 items that focus on
propensity to be engaged with content such as reading a book or watching a movie.
The Positive and Negative Affect Schedule (PANAS) is a validated 20-item survey
to assess the affect of each participant [55]. They will be asked to the extent they have felt specific
emotions on a Likert scale from 1 “Very Slightly or Not at All” to 5 “Extremely.”
A custom survey was also created to assess
analgesic medication use. The medication survey consists of 3 main questions to assess for the use of the
following: prescription medication, over-the-counter medication, or other medications. Prescription opioid
data will be converted to a standardized morphine milligram equivalent daily dose using the Centers for
Medicare & Medicaid Services “Opioid Oral Morphine Milligram Equivalent (MME) Conversion Table”
[56]. Endorsement of prescription medications will prompt additional items to collect the type of
medication, frequency of use, dose, happiness with one’s current prescribed medication regimen, and
interest in changing one’s current prescribed medication regimen.
We will also assess cLBP health care utilization in terms of frequency of steroid
injections, lower back surgery, emergency department visits, hospital admissions, and unplanned physician
visits over various periods.
Several custom surveys were developed for the study, including one
designed to assess satisfaction with each condition. Another assesses device usability, enjoyment or
difficulties, and the likelihood to continue treatment. Additional items will assess pain knowledge and pain
management skills use (eg, use of relaxation and controlled breathing during the previous 7 days). We will
also assess patient perception of the study arm using a single item administered to both groups in the 6-
month follow-up survey.
Data Collection, Quality Control, and Confidentiality
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General Approach
All questionnaires will be completed by participants electronically via the REDCap Cloud platform. We
will collect information at every stage of recruitment, randomization, and treatment in accordance with the
CONSORT (Consolidated Standards of Reporting Trials) guidelines [57]. The Western Institutional
Review Board approved this study. Given the safety of the device seen in past studies [7,31], Western
Institutional Review Board did not deem that this study would require Data Safety and Monitoring Board
oversight.
Compensation
Participants will receive a total of US $150 (US $6 per completed survey) for their participation in the
entire study. Two payments will be processed. The first payment will be distributed at the end of the 8-
week program (US $126 possible; prorated) and upon return of their VR headset (prepaid shipping will be
provided). The second payment will be distributed after the last follow-up survey (US $24 possible;
prorated). All payments will be in the form of an Amazon eGift Card.
In addition to their monetary compensation, all participants will be eligible to receive a gift VR headset 6
months after their completion of treatment if they complete 16 or more of the 21 surveys administered
during the active treatment phase, confirm their interest in receiving a VR headset, and return their VR
treatment study headset.
Safety Monitoring
Participants were provided with contact information and encouraged to contact as needed. Safety will be
monitored by following up with participants for any adverse events they communicate to the support staff.
Additionally, adverse experiences with using VR will be assessed using the question, “Did you experience
any motion sickness or nausea while using VR?” on 4-point with 0 (Never), 1 (Sometimes), 2 (Often), and
3 (Always). Similar to prior work, VR side effects will be assessed at the end of treatment [32].
Sample Size Determination
In terms of sample size considerations, a power analysis was performed using data from a recent at-home
cLBP study that we conducted. DVPRS pain intensity scores were collected from 39 individuals at
baseline, during, and immediately following a 21-day, skills-based VR intervention, and from 35
individuals at baseline, during, and immediately following an audio-only version of the 21-day program.
The average difference score was 1.48 for the VR group and was 0.756 for the audio-only group (on an 11-
point scale). Assuming an α level of .05 and 90% power, we would need 45 participants per group to
observe a treatment × time interaction. In case of high attrition (40%), we will randomize at least 75
participants per group and if possible up to 90 participants per group.
Statistical Analyses
Checks of assumptions underlying statistical procedures will be performed and all
corrective procedures will be applied as necessary. All analyses will involve 2-sided hypothesis tests, with
α=.05 and adjusted for any multiple comparisons within the family of tests as appropriate.
Group equivalence will be assessed through univariate tests of association between treatment groups
(EaseVRx/Sham VR) for all baseline demographic and clinical variables with chi-square and Kruskal–
Wallis tests applied as appropriate. If statistically significant differences between groups are found for any
variables (P<.05), those will be controlled for in the mixed models.
The data will be analyzed in a mixed-model framework (PROC GLIMMIX in SAS) with 3 explanatory
factors: treatment group, time, and time × treatment group. Treatment group, EaseVRx versus Sham VR,
will be specified as a between-subjects factor. Time will be specified as a within-subjects factor. The effect





of interest will be the time × treatment group effect which tests whether the treatment group influenced the
trajectory of the key variables over time.
The analytic method used will not involve imputing missing data for estimating the significance of the
effects specified in the model. However, the predicted values from the estimated model will be used for
reporting the findings. Given the safety of this treatment, there is no plan to conduct interim analyses.
The primary endpoint will be the time course of DVPRS-I Pain scale rating at baseline
(defined as the average of 3 DVPRS-I Pain Scale ratings obtained during the 2 weeks before
enrollment/randomization), at 8 weekly time points (twice per week) across the 8-week intervention, and
immediately following the intervention. We will use a linear mixed model as described above.
Several analyses will be proposed.
First, we will compare the PGIC scale at end of treatment and follow-ups.
Second, we will repeat similar analyses as above for 2 time points, baseline and immediately following the
8-week intervention for opioid drug use, PROMIS physical function, PROMIS sleep disturbance, PSEQ-2,
PCS, and CPAQ-8.
Finally, we will repeat similar analyses as above for 2 time points, the day immediately following the 8-
week intervention and 1 month after the intervention for DVPRS Pain Rating, opioid drug use, PROMIS
physical function, PROMIS sleep disturbance, PSEQ-2, PCS, and CPAQ-8.
A number of exploratory analyses will be conducted, all of which envisage the
above linear mixed modeling strategy with time points and variables as specified below.
First, we will assess Intervention × Time effects for a number of health-related outcome metrics (eg,
number of steroid injections, emergency department visits, hospital admissions) at 2 time points, Day 9
and immediately following the 8-week intervention.
Second, we will repeat the above analyses for the period comprising the end of the 8-week intervention
and at 3 and 6 months after the intervention.
Third, we will assess Intervention × Time effects for DVPRS Pain Rating, opioid drug use, PROMIS
physical function, PROMIS sleep disturbance, PSEQ-2, PCS, CPAQ-8, Patient satisfaction, and PANAS
for the periods comprising the 8-week intervention and at 1, 2, 3, and 6 months after the intervention. We
will use a 2-factor ANOVA with intervention (EaseVRx vs Sham VR) as an independent groups factor and
time as a dependent groups factor. Two-sided post hoc t-tests (adjusted for multiple comparisons) will be
utilized to isolate the locus of any effects.
Fourth, we will examine the time course of changes in pain skills (eg, controlled breathing, meditation)
from baseline, at the end of the 8-week intervention, and at 1, 2, 3, and 6 months after the intervention only
in the EaseVRx group. We will use a one-factor repeated-measures ANOVA. Two-sided post hoc t-tests
(adjusted for multiple comparisons) will be utilized to isolate the locus of any effects. When appropriate,
we will also utilize more robust statistical approaches that better address missing data and do not assume
distributional normality, such as bootstrapping.
In subsequent manuscripts, we will explore potential covariants of treatment response and possible
mechanisms of actions.
Results
The study was approved by the Western Institutional Review Board on July 2, 2020. The protocol
(NCT04415177) was registered on May 27, 2020. Recruitment for this study was completed in July 2020
and data collection will remain active until March 2021. In total, 186 participants were recruited. Multiple
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manuscripts will be generated from this study. The primary manuscript will be submitted for publication in
the winter of 2020.
Discussion
Protocol Overview
VR for chronic pain is an emerging area of behavioral medicine and science with heightened relevancy
during the COVID-19 pandemic. Many people are environmentally isolated and in need of effective home-
based pain care. This study protocol builds upon research that previously demonstrated that a 21-day
behavioral medicine skills VR program effectively reduced chronic pain intensity and pain-related
interference in activity, mood, sleep, and stress at the end of treatment. This study protocol addresses
several unknowns that remain in the scientific literature for VR for chronic pain. First, the study will test a
VR program of longer duration (56 days) and better aligns with the duration of current “gold-standard”
behavioral medicine for chronic pain, typically over 8 weeks of treatment time. Second, the study will test
treatment effects captured at the end of treatment and the durability of treatment effects measured at
several distal posttreatment time points (months 1, 2, 3, 6). Third, the study will include a Sham VR,
which will provide a visual treatment (2D nature scenes) that will control for the novelty of a headset
device and visual stimuli while omitting active behavioral medicine skills training. The inclusion of the
Sham VR group will also allow for exploration of the mechanisms of therapeutic VR. Fourth, a broad
range of relevant metrics have been included to characterize the psychological response to VR and aid in
the conduct of responder analyses and identification of subgroups; results could inform the development of
future tailored immersive therapeutics or study designs. Fifth, all study headsets will capture participant
use data, thereby allowing for the quantification of participant engagement and calculation of treatment
dose thresholds associated with treatment effects. Sixth, the study will capture analgesic medication use
and data on health care utilization specific to back pain; these data will allow for the conduct of
exploratory analyses examining the impact of VR on these factors for the subset of participants using these
treatments. Seventh, the study will occur within the context of the COVID-19 pandemic and will inform
self-administration of home-based VR and engagement during COVID-19 specifically.
The study design’s strength is that it will be conducted remotely and untethered from the medical system.
This design will increase the ecological validity of data derived from a home-based, national, pragmatic
sample of people with cLBP who will self-treat in their home environment. Additional aspects of
methodological rigor include participant blinding and randomization to the treatment group.
Limitations
The key limitations of this study protocol include the following. First, all data will be either self-reported
by the study participant or collected by the device (eg, use data for frequency and duration). Because the
study is pragmatic and will include a national sample, we will not verify medical diagnoses or prescribed
pain medication types and doses. Second, the study is specific to cLBP and findings may not generalize to
other pain conditions. However, we note that people with cLBP often report having 2 or more comorbid
pain conditions (Darnall et al, unpublished). As such, chronic back pain is not often experienced in
isolation.
Digital behavioral health treatment studies typically report relatively low treatment engagement rates
among participants with rates ranging between 20% and 60% [32,58-60]. While prior research evidenced
good engagement for therapeutic VR for chronic pain, engagement rates for a 2D Sham VR are unknown
and we may risk disparate engagement rates between the 2 treatment groups. While the study team has
endeavored to minimize such discrepancy by enhancing the Sham VR’s face validity, we anticipate some
treatment group discrepancy would naturally occur if one treatment is experienced broadly as less
rewarding or effective.
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Our plan to enroll a national sample over the internet lends a mix of strengths and limitations. Participants
recruited via the internet are likely to be more technologically savvy than the general population seeking
medical care from a health care system. It could be argued that our study results may not generalize to
people who are less likely to engage with the internet and technology. However, we also note that
treatment studies that are conducted within traditional medical settings typically involve more in-person
contacts and enhanced placebo effects (ie, halo effect) that would be likely to yield more positive treatment
expectations and outcomes. We underscore that our study design will not benefit from medical setting
placebo effects.
Finally, aligning with prior work, data on adverse effects will be collected at the end of the study. We
acknowledge that these methods introduce the potential for recall bias. However, previous study
participants reported easily recalling adverse experiences at the end of the study due to their specificity and
salience (eg, cybersickness) [32].
Conclusions
This study will be one of the most rigorous in assessing the impact of self-administered VR therapy in
community-based individuals with chronic lower back pain and the first to use a placebo VR therapy
program. Its remote design will allow it to be completed during a global pandemic in a pragmatic and
nationally representative sample. This will also be the first study to assess VR therapy’s durability for
chronic pain over a 6-month posttreatment follow-up period. Results from this study will provide critical
data on how individuals with chronic lower back pain may use self-administered VR therapy at home for
symptom management and functional improvement.
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cLBP chronic lower back pain
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PGIC Patient’s Global Impression of Change
PHQ Patient Health Questionnaire
PROMIS Physical Function and Sleep Disturbance
PSEQ Pain Self-Efficacy Questionnaire
SUS System Usability Scale
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Figure 1
Timeline of protocol activities: This figure depicts each of the steps that participants in this study will go through,
starting from the moment they receive an advertisement for the study until the end of our follow-up assessments.
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Figure 2
Interventions: This figure depicts the Skills-Based VR condition and control VR condition.
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Table 1
Variable/category, measure name, rank, and number of items for all measures.
Open in a separate window
DVPRS: Defense and Veterans Pain Rating Scale.
PROMIS: Physical Function and Sleep Disturbance.
VR: virtual reality.
The 4 questions were selected from the PCS to decrease participant burden.
cLBP: chronic lower back pain.
Variable or Category Measure
Primary Outcome
 Pain intensity/Pain interference
(activity, mood, sleep, stress)
DVPRS-I  Pain Scale and DVPRS-II Pain Scale Measures [36]
Secondary Outcomes
 Global impression of change Patient’s Global Impression of Change (PGIC) [38]
 Physical function PROMIS  Physical Function [40]
 Sleep disturbance PROMIS Sleep Disturbance [41]
 Acceptability Custom Patient Satisfaction
 Adherence Custom Device Utilization survey
 Adherence VR  usage data
 Pain self-efficacy Pain Self-Efficacy Questionnaire (PSEQ) [51] (general) and Custom Pain S
as a referent (inside the VR headset and outside the VR headset)
 Pain acceptance Chronic Pain Acceptance Questionnaire (CPAQ) [52]
 Pain catastrophizing Pain Catastrophizing Scale (PCS ) [49]
 Pain medication Custom Analgesic Medication Use Survey
 Health care utilization Custom health care utilization survey for cLBP
 Other measures  
 Assessment of affect Positive and Negative Affect Schedule (PANAS) [55]
 Susceptibility to virtual reality
treatment
Involvement subscale from the Immersive Tendency Questionnaire (ITQ – 
 Acceptability System Usability Scale (SUS) [53]
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Open in a separate window
DVPRS: Defense and Veterans Pain Rating Scale.
PGIC: Patient’s Global Impression of Change.
PROMIS: Physical Function and Sleep Disturbance.
PCS: Pain Catastrophizing Scale.
CPAQ-8: Chronic Pain Acceptance Questionnaire.
VR: virtual reality.
PANAS: Positive and Negative Affect Schedule.













DVPRS-I  and DVPRS-
II
X X X X X
PGIC    X X
PROMIS  physical
function
X   X X
PROMIS sleep
disturbance
X   X X
Pain self-efficacy
measures
X   X X
PCS X   X X
CPAQ-8 X   X X
Opioid use X   X X
Health care utilization X   X  
Patient satisfaction     X
Device utilization   X X  
VR  usage data   X X  
PANAS X   X  
SUS    X  
ITQ —involvement
subscale
X     
Perceived treatment
assignment
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SUS: System Usability Scale.
ITQ: Immersive Tendencies Questionnaire.
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